Prescriptions jump for EpiPen alternatives

Concerns over the soaring cost of Mylan's (NASDAQ:MYL) EpiPen, plus increased competition, appear to have taken a toll on sales of the brand-name allergy shot.

Data from the Athenahealth network shows that prescriptions for EpiPen alternatives have quadrupled since the beginning of 2017.

Put another way, the brand-name product's market share has fallen from around 95% to around 71% in February.